Search

Author/Creator Kwei, Kevin

1. Phase 1b/2 study of ibrutinib and lenalidomide with dose-adjusted EPOCH-R in patients with relapsed/refractory diffuse large B-cell lymphoma*. Issue 9 (29th July 2021)

Authors:
Wilson, Wyndham H.; Phillips, Tycel; Popplewell, Leslie; de Vos, Sven; Chhabra, Saurabh; Kimball, Amy S.; Beaupre, Darrin; Huang, Da Wei; Wright, George; Kwei, Kevin; Ping, Jerry; Neuenburg, Jutta K.; Staudt, Louis M.
Journal:
Leukemia & lymphoma
Issue:
Volume 62:Issue 9(2021)
Page Start:
2094
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Safety and activity of ibrutinib in combination with durvalumab in patients with relapsed or refractory follicular lymphoma or diffuse large B‐cell lymphoma. Issue 1 (6th November 2019)

Authors:
Herrera, Alex F.; Goy, Andre; Mehta, Amitkumar; Ramchandren, Radhakrishnan; Pagel, John M.; Svoboda, Jakub; Guan, Shanhong; Hill, John S.; Kwei, Kevin; Liu, Emily A.; Phillips, Tycel
Journal:
American journal of hematology
Issue:
Volume 95:Issue 1(2020:Jan.)
Page Start:
18
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Up to 6.5 years (median 4 years) of follow-up of first-line ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma and high-risk genomic features: integrated analysis of two phase 3 studies. Issue 6 (12th May 2022)

Authors:
Burger, Jan A.; Robak, Tadeusz; Demirkan, Fatih; Bairey, Osnat; Moreno, Carol; Simpson, David; Munir, Talha; Stevens, Don A.; Dai, Sandra; Cheung, Leo W. K.; Kwei, Kevin; Lal, Indu; Hsu, Emily; Kipps, Thomas J.; Tedeschi, Alessandra
Journal:
Leukemia & lymphoma
Issue:
Volume 63:Issue 6(2022)
Page Start:
1375
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗